Venture Capital & Emerging Companies

You are using an unlicensed and unsupported version of DotNetNuke Enterprise Edition. Please contact for information on how to obtain a valid license.

We know how to help you turn your ideas into reality. Our attorneys can provide you with legal services that evolve as your enterprise does — from start-up to successful exit. 

Because we work to understand your business, we’ll help examine your corporate requirements, intellectual property protection, employment issues, and regulatory and compliance needs, and assess how these impact your bottom line. That’s what we’ve already done for many major companies and investors in the information technology, digital media, social media, life sciences, health care, and energy and clean technology sectors.

We’re experienced in representing clients in all types of financings — from early- or seed-stage investments through later stages. We provide counsel to companies, investors, and financial advisors in a range of sophisticated transactions.

Quick Facts

  • More than 150 completed venture capital transactions since 2010, with an aggregate deal value of over $1.9 billion
  • Represent founders, companies, and venture capital and other investors
  • All stages — from early- or seed-stage investments through subsequent multi-investor and late-stage financing
  • Initiate introductions between our start-up clients and our network of angel investors and venture capital firms
  • Recommended by The Legal 500 United States for Mergers, Acquisitions and Buyouts - Venture Capital and Emerging Companies

Areas of Focus

  • Start-Up services
    • Incorporation
    • Intellectual property protection
    • Option plans
    • Proprietary information agreements
    • Restricted stock agreements
    • Stockholder agreements

  • Corporate transactions
    • Commercial contracts
    • International transactions
    • Joint ventures
    • Licensing
    • Mergers and acquisitions
    • Outsourcing agreements
    • Strategic alliances

  • Employee, labor, and benefits counseling
    • Compensation arrangements
    • Employee handbooks
    • Immigration
    • Noncompete protection

  • Financings
    • Alternative public offerings
    • Cross-border financings
    • Debt and equity structures
    • IPOs
    • Private placements
    • Seed stage and “angel” financings
    • Venture financings

  • Fund formation
    • Broker-dealer and investment advisor regulatory compliance
    • Investment advisory agreements
    • Limited liability company agreements
    • Limited partnership agreements
    • Private placement memoranda

  • Government relations
    • Federal government regulations
    • Lobbying

  • Intellectual property
    • Copyrights
    • Patents
    • Privacy and security
    • Technology transfer
    • Trademarks

  • Tax structuring and advice
    • Minimizing tax on equity grants
    • Structuring transactions

Sort by: Name  Title  Office

Boston 617-348-3084
Brady Berg

Brady Berg


San Francisco (415) 432-6003
New York (212) 692-6869
Boston (617) 348-3097
San Diego (858) 314-1533
San Francisco (415) 432-6000
Hannah C. Coman

Hannah C. Coman


Boston (617) 348-1703
John P. Condon

John P. Condon


Boston (617) 348-4453
Peter Demuth

Peter Demuth


Boston (617) 348-3008
New York (212) 692-6223
New York (212) 692-6730
Samuel Effron

Samuel Effron


New York (212) 692-6810
Boston (617) 348-1640
Boston 617-348-3051
Boston 617-348-1735
Boston (617) 348-1834
Kristin A. Gerber

Kristin A. Gerber


Boston 617-348-3043
San Diego (858) 314-1515
San Francisco (415) 432-6000
Boston (617) 348-1623
Kanasha S. Herbert

Kanasha S. Herbert


Boston 617-348-3015
Boston (617) 348-1715
Boston (617) 348-3093
Boston (617) 239-8491
New York (212) 692-6768
San Diego (858) 314-1509
San Francisco (415) 432-6104
Washington, DC (202) 434-7452
San Diego (858) 314-1519
Boston (617) 348-1841
R. Robert Popeo

R. Robert Popeo


Boston (617) 348-1716
Linda Rockett

Linda Rockett


Boston (617) 348-4888
Boston (617) 348-1798
New York (212) 692-6732
Bram Shapiro

Bram Shapiro


Boston (617) 348-1610
Sahir Surmeli

Sahir Surmeli


Boston (617) 348-3013
Boston (617) 348-1759
Garrett M. Winslow

Garrett M. Winslow


Boston (617) 348-3028
Ran Zioni

Ran Zioni

International Member

Washington, DC (202) 434-7456
Dean G. Zioze

Dean G. Zioze


Boston (617) 348-4795

Representative Experience

  • Represented ClearSky Power + Technology Fund I in the following financings: $5 million Series A financing of Sentient Energy, Inc.; $22.5 million Series D financing of iControl Networks, Inc.; and $17.55 million Series B financing of Modular Wind Energy, Inc.
  • Represented Intercept Pharmaceuticals, Inc. in its August 2012 $30 million Series C financing led by OrbiMed Advisors and Genextra.
  • Represented AccuVein, Inc. in its July 2012 $7.1 million financing led by MVM Life Sciences Fund, Bessemer Venture Partners, Tullis, and Lynch Foundation.
  • Represented Tarsa Therapeutics, Inc. in its March 2012 $28 million Series B financing led by Foresite Capital, Novo A/S, MVM Life Sciences Fund, and Quaker Partners.
  • Represented GreatPoint Energy, Inc. in its $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Compass Labs, Inc. in its February 2012 $6 million financing led by Presidio Ventures and NEA (New Enterprise Associates).
  • Represented Extole, Inc. in its January 2012 $10.2 million financing led by Shasta Ventures, Trident Capital, Redpoint Ventures, and Norwest Venture Partners.
  • Represented Oxford Bioscience Partners in its December 2011 $20 million Series C financing of Glori Energy, a leader in sustainable, enhanced oil recovery and provider of the AERO (Activated Environment for Recovery of Oil) System. Gentry Venture Partners led the investment. Other investors included Advantage Capital Partners, Energy Technology Ventures (a GE, NRG Energy, and ConocoPhillips joint venture), GTI Ventures, Kleiner Perkins Caufield and Byers (KPCB), Malaysian Life Sciences Capital Fund, and the Omzest Group.
  • Represented Sera Prognostics, Inc. in its November 2011 $19.3 million Series A financing led by Interwest Partners, Domain Partners, Catalyst Health Ventures, Osage University Partners, and UpStart Life Sciences Capital.